Coherence Neuro, a startup developing brain implants to treat cancer, has raised $45 million in a Series A funding round co-led by Peter Thiel's Founders Fund and the OpenAI Startup Fund. The investment, which also drew participation from Lux Capital, Olive Capital, and 8VC, will finance the company's first chronic human trial of its SOMA implant as a treatment for glioblastoma, an aggressive brain cancer with a grim prognosis. Coherence detailed its plans in a post, stating that the funds will also support its pursuit of FDA breakthrough device designation and expansion into other malignancies, including pancreatic cancer.
The significance of the announcement lies in its potential to upend the standard of care for glioblastoma, which has claimed prominent figures such as Senators Ted Kennedy and John McCain. Current treatments offer limited survival benefits, but Coherence's approach leverages the emerging understanding that tumors emit unique electrical signals. The SOMA implant, roughly the size of a button, monitors these signals and delivers electrical stimulation to disrupt tumor development. It works in concert with a removable wearable worn above the ear and a companion app that tracks symptoms and therapy history in real time. Several consenting patients have had the device implanted during surgery to remove glioblastoma tumors, with those initial tests focused on establishing safety.
If the chronic trial succeeds, Coherence's technology could shift the treatment paradigm from reactive to proactive, arresting cancer development before it becomes advanced. The company, founded in 2022 by Elise Jenkins and Ben Woodington, is also expanding its multi-disciplinary team to accelerate research and development. The startup's progress comes amid broader efforts to tackle brain cancer; other entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are developing novel medications for glioblastoma, underscoring the urgent need for new options. Coherence's implant-based strategy represents a novel convergence of neuroscience and oncology, and the backing of high-profile investors like Thiel and OpenAI signals confidence in its potential to commercialize a therapy that could change outcomes for patients facing a devastating diagnosis.
The funding round and planned trial mark a critical step for Coherence as it navigates regulatory pathways and clinical validation. With FDA breakthrough designation, the company could expedite development, bringing the implant closer to market. As the startup advances its R&D programs, industry observers will watch whether its electrical disruption approach can deliver on the promise of a new cancer treatment modality. For now, the Series A provides the resources to test that promise in humans, a milestone that could redefine glioblastoma therapy and attract further investment to the intersection of bioelectronics and oncology.
